Vikasolum

General characteristics. Structure:

Active agent - Vikasolum of 0,015 g.

Excipients: lactose-0,07 of, starch potato-0,014, 
calcium stearate-0,001 of.

Description. Tablets of white or almost white color, round, a ploskotsilindrichesky form, with a facet.

Pharmacological properties:

Has haemo static effect. 

Drug of group of vitamin K. Increases coagulability of blood due to strengthening of development in a liver of factors 11, V 11, 1 H, H. The effect is shown in 12-18 h after introduction in oil. In blood the prothrombin (a factor 11) in the presence of thromboplastin and calcium ions, with the participation of proconvertin (V11 factor) of factors 1 X and X passes into thrombin under the influence of which fibrinogen turns into the fibrin making a basis  of a clot (blood clot). At insufficiency  of vitamin K  which synthetic homolog is Menadionum there is  a raised bleeding. Substratno stimulates K-vitaminreduktazu, activating  vitamin K and providing its participation in hepatic synthesis K-vitaminozavisimykh  of plasma factors  of a hemostasis. After introduction in oil it is easily and quickly soaked up. 

Pharmacokinetics. After introduction in oil it is easily and quickly soaked up. Having passed  a cycle of metabolic activation, is oxidized to a thiol form. It is removed by kidneys.

Indications to use:

Bleeding (bleedings) against the background of a prothrombinopenia: obturatsionny jaundice, hepatitis, parenchymatous and capillary bleedings at wounds, surgeries, a peptic and  radial illness: hemorrhoidal, uterine, pulmonary and long nasal bleedings: the hemorrhagic phenomena at premature: neodicoumarin overdose, etc. indirect anticoagulants.

Route of administration and doses:

Inside the adult – on 15-30 mg/days, children - 2-15 mg/days, depending on age.

Features of use:

Are not described.

Side effects:

Hemolitic anemia, hyperbilirubinemia, jaundice, especially at premature, hemolysis at newborn children with inborn deficit glyukozo-6-fosfatdegidrogenazy.

Interaction with other medicines:

Weakens effects of indirect anticoagulants.

Contraindications:

Hypersensitivity, hypercoagulation, thrombembolia, hemolitic disease of newborns.

Overdose:

Cases are not described.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C.  In places unavailable to children.

Issue conditions:

According to the recipe

Packaging:

On 30 tablets in banks from orange glass or from polymeric materials. On 10 tablets in a blister strip packaging. To bank of orange glass or 3 blister strip packagings with the application instruction place in a pack from a cardboard. 100 cans from polymeric materials with the application instruction place in a box from a cardboard.